Price
$32.42+14.48%Social Signal Score
Analyst Ratings
1 analystRevenue
$24.95B+385.98%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Dominic William Blakemore
- Sector
- Consumer Cyclical
- Industry
- Restaurants
- Employees
- 590,000
- Beta
- 0.63
- Country
- GB
- Piotroski score
- 5 / 9 (Middling)
- Altman Z-score
- 3.16
Financials
Revenue
$24.95B+386.0%Net Income
$1.07B+649.1%EBITDA
$2.49B+622.5%Free Cash Flow
$1.29B+897.0%EPS (diluted)
$0.63+760.7%Shares Outstanding (diluted)
1.70B-12.7%Operating Expenses
$0.00Cash & Debt
$523.00MReturn of Capital
$744.94MDividend per Share
$0.26Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $46.11B | $1.87B | $1.10 |
| 2024 | $55.05B | $1.84B | $0.81 |
| 2023 | $31.07B | $1.60B | $0.75 |
| 2022 | $25.51B | $1.11B | $0.63 |
| 2021 | $17.91B | $357.00M | $0.20 |
| 2020 | $19.94B | $133.00M | $0.08 |
| 2019 | $24.88B | $1.17B | $0.74 |
| 2018 | $22.87B | $1.16B | $0.73 |
| 2017 | $22.57B | $1.16B | $0.71 |
| 2016 | $19.61B | $992.00M | $0.69 |
| 2015 | $17.59B | $869.00M | $0.55 |
| 2014 | $16.85B | $865.00M | $0.52 |
| 2013 | $17.56B | $429.00M | $0.26 |
| 2012 | $27.28B | $588.77M | $0.35 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from CMPGY's reported EPS growth of 9.2% a year over 13 years.
- EPS in 5 years
- $1.71
- Implied price
- $53.01
- Return from $33.38
- 9.7% a year
To earn 15.0% a year on these assumptions you'd need to buy at $26.36 — -21.0% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 21 | 26 | 31 | 36 | 41 |
|---|---|---|---|---|---|
| -0.8% | -7.8% | -3.8% | -0.4% | 2.7% | 5.4% |
| 4.2% | -3.2% | 1.1% | 4.7% | 7.8% | 10.7% |
| 9.2% | 1.5% | 5.9% | 9.7% | 13.0% | 16.0% |
| 14.2% | 6.1% | 10.8% | 14.7% | 18.2% | 21.3% |
| 19.2% | 10.8% | 15.6% | 19.7% | 23.4% | 26.6% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
40-52.94%Social Signal Score
Mentions (66)
- Newsmarketbeat.com·12h ago·Negative
Compass Pathways Sees Potential Fast FDA Review for Psilocybin Depression Treatment Compass Pathways NASDAQ: CMPS has completed its application to the U.S. Food and Drug Administration for COMP360, its investigational synthetic psilocybin treatment for treatment-resistant depression, and expects to be ready to launch by the end of the year, subject to approval.
View source ↗ - Newsbusinesswire.com·3d ago·Positive
Compass Pathways to Participate in 9th Annual Evercore Healthcare Conference on December 1 LONDON & JERSEY CITY, N.J.--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that management will attend the 9th Annual Evercore Healthcare Conference on December 1, 2026 and will participate in a fireside chat at 3:25pm ET. A live audio webcast of the fireside
View source ↗ - Newsbusinesswire.com·11d ago·Positive
Compass Pathways to Participate in Jefferies Global Healthcare Conference on November 18th and 19th LONDON & JERSEY CITY, N.J.--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that management will attend the Jefferies Global Healthcare Conference on November 18 and 19, 2026 and will participate in a fireside chat on November 18 at 9:00am GMT and a p
View source ↗ - Newsmarketbeat.com·15d ago·Negative
Compass Q3 Earnings Call Highlights Compass NYSE: COMP reported record third-quarter revenue and profit as cost cuts following its Anywhere acquisition helped offset a difficult housing market, but executives warned that weaker pending home sales could weigh on fourth-quarter results.
View source ↗ - Newsseekingalpha.com·16d ago·Positive
Compass, Inc. (COMP) Q3 2026 Earnings Call Transcript Compass, Inc. ( COMP ) Q3 2026 Earnings Call November 5, 2026 5:00 PM EST Company Participants Soham Bhonsle - Head of Investor Relations Robert Reffkin - Founder, Chairman & CEO Scott Wahlers - CFO & Principal Financial Officer Conference Call Participants Jason Helfstein - Oppenheimer & Co. Inc., Research Division Elizabeth Langan - Barclays Bank PLC, Research Division Ryan McKeveny - Zelman & Associates LLC Dae Lee - JPMorgan Chase & Co, R
View source ↗ - Newsseekingalpha.com·16d ago·Positive
Compass: Lofty Market Share Gains As The Company Tightens Its Grip On The Industry Compass offers a compelling diversification play as investors rotate from AI stocks to real economy names. Despite strong Q3 results and industry outperformance, COMP shares are down ~20% since August and ~15% year-to-date. I reiterate my 'Buy' rating, citing COMP's position as the largest U.S. real estate brokerage following its Anywhere Real Estate acquisition.
View source ↗ - Newsglobenewswire.com·16d ago·Negative
Compass Therapeutics Presents Novel Mechanism of Action Data for CTX-10726 (PD-1 x VEGF-A Bispecific Antibody) at the SITC 2026 Annual Meeting CTX-10726, a PD-1 x VEGF-A bispecific antibody discovered and engineered at Compass, exhibits a unique mechanism of action that has not been previously reported in this class of drugs, characterized by VEGF-A-dependent cleavage of PD-1 receptors from T cells resulting in conversion of PD-1 positive T cells into PD-1 negative T cells. PD-1 receptor cleava
View source ↗ - Newszacks.com·17d ago·Negative
Compass, Inc. (COMP) Meets Q3 Earnings Estimates Compass, Inc. (COMP) came out with quarterly earnings of $0.07 per share, in line with the Zacks Consensus Estimate . This compares to a loss of $0.01 per share a year ago.
View source ↗ - Newsbusinesswire.com·17d ago·Neutral
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) LONDON & JERSEY CITY, N.J.--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to nine newly hired non-executive employees. The equity awards were granted on November 2, 20
View source ↗ - Newsprnewswire.com·17d ago·Negative
Compass, Inc. Reports Record Third Quarter 2026 Results All-time Q3 Records for Revenue, Net Income, Adjusted EBITDA and Operating Cash Flow Q3 Reven ue +12% YoY1; GAAP Net Income $62 Million; Adjusted EBITDA2 $306 Million Operating Cash Flow $248 Million; Cash Balance Increases to $841 Million NEW YORK, Nov. 5, 2026 /PRNewswire/ -- Compass, Inc. ("Compass" or "the Company") (NYSE: COMP), a global real estate services company with a presence in every major U.S. city and approximately 120 countri
View source ↗ - Newsmarketbeat.com·17d ago·Negative
Compass Diversified Q3 Earnings Call Highlights Compass Diversified NYSE: CODI reported higher third-quarter adjusted earnings from its subsidiaries and narrowed its full-year outlook, as growth in its consumer businesses helped offset weaker industrial results.
View source ↗ - Newsbusinesswire.com·18d ago·Positive
Compass Pathways to Participate in Stifel 2026 Healthcare Conference on November 11th LONDON & JERSEY CITY, N.J.--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that management will attend the Stifel 2026 Healthcare Conference on November 11, 2026 and will participate in a fireside chat at 8:40am ET. A live audio webcast of the fireside chat will b
View source ↗ - Newsfool.com·18d ago·Neutral
Compass Pathways: 3 Key Takeaways for Long-Term Investors COMPASS will complete its New Drug Application submission within two weeks. Interventional psychiatrists surveyed show 90% willingness to prescribe COMP360.
View source ↗ - Newsmarketbeat.com·19d ago·Negative
Compass Pathways Q3 Earnings Call Highlights Compass Pathways NASDAQ: CMPS said it expects to complete its rolling New Drug Application submission for COMP360, its investigational psilocybin treatment for treatment-resistant depression, within two weeks, as the company prepares for a potential U.S. launch in the first half of 2027.
View source ↗ - News247wallst.com·20d ago·Positive
Rocket Companies Jumps 9%, Compass and Zillow Surge 8% as Treasury Yields Retreat Rate-sensitive housing stocks are rallying as Treasury yields retreat, and Rocket Companies (NYSE:RKT | RKT Price Prediction) is out in front. Rocket Companies stock is at $13.96, up 9%, in late-day trading.
View source ↗ - Newsglobenewswire.com·20d ago·Neutral
Compass Therapeutics to Participate in Upcoming November Investor Events BOSTON, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will participate in the following investor events during the month of November/this quarter. Details are as follows: Guggenheim 3rd Annual Healthcare Innovation Co
View source ↗ - Newsfool.com·20d ago·Positive
1 Reason Compass Pathways Is Worth a Second Look This Month FDA approval could provide a significant catalyst for shares. Wall Street's average price target implies approximately 95% upside.
View source ↗ - Newsglobenewswire.com·23d ago·Negative
COMP Shareholders Have Rights – If you Lost Money Investing in Compass, Inc. Contact Robbins LLP for Information About Recovering Your Losses Compass, Inc. (COMP) faces allegations it made false and misleading statements in connection with its January 2026 Merger with Anywhere Real Estate Inc.
View source ↗ - Newszacks.com·24d ago·Neutral
Compass, Inc. (COMP) Earnings Expected to Grow: What to Know Ahead of Next Week's Release Compass (COMP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
View source ↗ - Newsseekingalpha.com·25d ago·Neutral
Compass Pathways: A Compelling Opportunity In A Large And Underserved Market COMPASS Pathways is currently engaged in a rolling submission and review with the FDA for COMP360 and expects a commercial launch in the first half of 2027. COMPASS is initially targeting the TRD market, which is large and underserved. SPRAVATO has already established the commercial potential of this market, and COMP360 could benefit from reduced dosing frequency. Recent industry M&A also validates the commercial potent
View source ↗ - Newsbusinesswire.com·26d ago·Positive
Compass Pathways to Announce Third Quarter 2026 Financial Results on November 3, 2026 LONDON & JERSEY CITY, N.J.--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that it will release financial results for the third quarter ended September 30, 2026, and provide an update on recent developments, on November 3, 2026. Compass management will host a conf
View source ↗ - Newsnewsfilecorp.com·26d ago·Neutral
Compass Gold Signs MOU for the Construction of a Gravity Concentration Plant at the Massala Gold Project, Mali MOU offers modular plant construction solution and operating framework to support near-term pathway to production Toronto, Ontario--(Newsfile Corp. - October 27, 2026) - Compass Gold Corp. (TSXV: CVB) (OTC Pink: COGDF) ("Compass" or the "Company") is pleased to announce it has entered into a non-binding memorandum of understanding ("MOU") with Mali-based INDUSTRIE MALIENNE POUR L'AGRICU
View source ↗ - Newsglobenewswire.com·29d ago·Neutral
Compass Therapeutics Announces Publication of Phase 2/3 COMPANION-002 Results for Tovecimig in the Journal of Clinical Oncology and Oral Presentation at ESMO 2026 BOSTON, Oct. 24, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced the publication of results from the positive Phase 2/3 COMPANION-002 study of tovecimig in
View source ↗ - Newsglobenewswire.com·31d ago·Neutral
Compass Diversified Announces Third Quarter 2026 Earnings and Conference Call Information WESTPORT, Conn., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Compass Diversified (NYSE: CODI) (“CODI” or the “Company”), an owner of leading middle-market branded consumer and industrial businesses, announced today that it plans to report financial results for the third quarter ended September 30, 2026 on Wednesday, November 4, 2026 after market close. The Company has scheduled a conference call at 5:00 p.m. ET on No
View source ↗ - Newsseekingalpha.com·32d ago·Positive
Compass Pathways: Built The FDA's Way, Valued At 0.57x Spravato's Sales COMPASS Pathways is rated Buy, with high risk, based on strong trial design and imminent FDA review for COMP360 in treatment-resistant depression. COMP360's Phase 3 trials matched FDA guidance, achieved statistically significant efficacy similar to Spravato, and are positioned for a fast-track FDA decision this quarter. CMPS holds $433.3 million in cash, funding operations into 2028, with valuation implying investors pay 0.5
View source ↗ - Newsprnewswire.com·37d ago·Neutral
Compass, Inc. to Announce Third Quarter Results on November 5 NEW YORK, Oct. 16, 2026 /PRNewswire/ -- Compass, Inc. ("Compass" or the "Company") (NYSE: COMP), today announced its third quarter 2026 financial results will be released after market close on Thursday, November 5, 2026. The Company will host a conference call and webcast to discuss its results that afternoon at 5:00 p.m.
View source ↗ - Newsprnewswire.com·38d ago·Negative
FACTS Introduces FACTS Compass™, a Scholarship Administration Platform for the Federal Scholarship Tax Credit New Platform Helps Scholarship Granting Organizations Support Students Across Public and Private Schools LINCOLN, Neb., Oct. 15, 2026 /PRNewswire/ -- FACTS, a Nelnet company (NYSE: NNI), today announced FACTS Compass™, a scholarship administration platform designed to help Scholarship Granting Organizations (SGOs) administer the Federal Scholarship Tax Credit (FSTC) and build a more conn
View source ↗ - Newsglobenewswire.com·38d ago·Negative
Compass Lexecon Continues to Expand Competition Expertise With Appointment of Stéphane Dewulf as Head of Brussels Former European Commission Economist Adds to Compass Lexecon's Cross-Border Merger Control and Antitrust Experience Across Digital, Technology, Media, Telecoms and Energy Former European Commission Economist Adds to Compass Lexecon's Cross-Border Merger Control and Antitrust Experience Across Digital, Technology, Media, Telecoms and Energy
View source ↗ - Newsbusinesswire.com·39d ago·Negative
Securities Fraud Investigation Into Compass, Inc. (COMP) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Compass, Inc. (“Compass” or the “Company”) (NYSE: COMP) on behalf of investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON COMPASS, INC. (COMP), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSU
View source ↗ - Newsglobenewswire.com·39d ago·Neutral
Compass Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BOSTON, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced it granted stock options to a new employee under the Company's 2025 Inducement Plan and as a material inducement to their employment in accordance with Nasdaq Listing Rule 5635(c)(
View source ↗ - Newsbusinesswire.com·39d ago·Positive
Compass Pathways Joins Forces with Leading Mental Health Organizations to Mark First-Ever U.S. Treatment-Resistant Depression (TRD) Awareness Day LONDON & JERSEY CITY, N.J.--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, today announced the first-ever TRD Awareness Day in the U.S., a day dedicated to recognizing and advocating for individuals, caregivers and commu
View source ↗ - Newsglobenewswire.com·40d ago·Neutral
Compass Lexecon Names Adel Turki President and Niall H. MacMenamin Deputy President New North America Leadership Structure Positions Compass Lexecon for Continued Excellence Across Antitrust, Securities, Finance, Valuation, Damages and Complex Litigation Matters New North America Leadership Structure Positions Compass Lexecon for Continued Excellence Across Antitrust, Securities, Finance, Valuation, Damages and Complex Litigation Matters
View source ↗ - Newsbusinesswire.com·44d ago·Neutral
Compass, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - COMP LOS ANGELES--(BUSINESS WIRE)---- $COMP--Compass, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - COMP.
View source ↗ - Newsbusinesswire.com·44d ago·Negative
COMP Investors Have Opportunity to Lead Compass, Inc. Securities Fraud Lawsuit with SBS Law LOS ANGELES--(BUSINESS WIRE)---- $COMP--COMP Investors Have Opportunity to Lead Compass, Inc. Securities Fraud Lawsuit with SBS Law.
View source ↗ - Newsnewsfilecorp.com·46d ago·Negative
Compass Gold Announces Appointment of Target IR and Provides Corporate and Mali Update Toronto, Ontario--(Newsfile Corp. - October 7, 2026) - Compass Gold Corp. (TSXV: CVB) (OTC Pink: COGDF) ("Compass" or the "Company") announces the appointment of Target IR & Communications to support the Company's investor relations and communications program and provides updates on its corporate communications initiatives and activities in Mali. Appointment of Investor Relations Firm Compass has entered into
View source ↗ - Newsbusinesswire.com·51d ago·Neutral
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to one senior leader and ten newly hired non-executive employees. The equity awards for the senior lea
View source ↗ - Newsglobenewswire.com·52d ago·Negative
Compass Diversified Declares Third Quarter 2026 Distributions on Series A, B and C Preferred Shares WESTPORT, Conn., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Compass Diversified (NYSE: CODI) (“CODI” or the “Company”), an owner of leading middle market businesses, announced today that its Board of Directors (the “Board”) has declared a quarterly cash distribution for each of its three preferred share series.
View source ↗ - Newsseekingalpha.com·52d ago·Positive
Compass Minerals International Continues To Trade On The Cheap Even After Soaring Compass Minerals International remains a ‘buy' as fundamentals strengthen and shares trade at a compelling valuation. Revenue and profitability improved despite volume declines, driven by higher salt prices and operational discipline. Salt segment pricing power offset lower highway salt volumes, while Plant Nutrition benefited from intentional portfolio adjustments.
View source ↗ - Newsbusinesswire.com·53d ago·Neutral
Compass Pathways Appoints Kelley Boucher as Chief People Officer LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced the appointment of Kelley Boucher as Chief People Officer, effective today. This appointment strengthens the Compass executive team as the company continues to scale in support of its mission to bring the first classic psyche
View source ↗ - Newsbarrons.com·58d ago·Neutral
Inside The War Between Real Estate's Compass and Zillow How a court case and listing battle is shaping up.
View source ↗ - Newsmarketbeat.com·59d ago·Negative
Compass Pathways Targets Q4 COMP360 NDA Completion, Eyes 2027 Launch Compass Pathways NASDAQ: CMPS executives said the company remains on track to complete its rolling New Drug Application submission for COMP360 in the fourth quarter, while preparing commercial infrastructure for a potential U.S. launch following FDA approval and federal rescheduling.
View source ↗ - Newsseekingalpha.com·60d ago·Negative
Compass Therapeutics: A Promising, But Shrinking, Window Of Opportunity Compass Therapeutics faces a major setback after tovecimig failed to show an overall survival benefit in biliary tract cancer. CMPX plans to pursue a BLA submission for tovecimig despite FDA guidance recommending a new survival-focused trial. Financial runway extends into 2028, but delays or regulatory setbacks could force CMPX to raise capital from a weakened position.
View source ↗ - Newsmarketbeat.com·61d ago·Negative
Compass Pathways Targets 2027 COMP360 Launch After Positive Phase III Depression Data Compass Pathways NASDAQ: CMPS said it remains on track to complete its rolling New Drug Application submission for COMP360 in the fourth quarter of 2026, following positive Phase III studies of its synthetic psilocybin treatment in treatment-resistant depression, or TRD.
View source ↗ - Newsmarketbeat.com·61d ago·Negative
Compass Pathways Eyes 2027 COMP360 Launch as FDA Review Advances Compass Pathways NASDAQ: CMPS expects to complete its new drug application submission for COMP360, its investigational psilocybin treatment for treatment-resistant depression, in the fourth quarter, with a potential U.S. launch in the first half of 2027, executives said at the Morgan Stanley Global Healthcare Conference.
View source ↗ - Newsbenzinga.com·61d ago·Negative
Compass Therapeutics Craters, FDA Pushes Survival-Trial Demand for Cancer Drug Compass Therapeutics, Inc. (NASDAQ:CMPX) shares are trading lower on Tuesday as the FDA feedback raises new questions about the timing and requirements for its tovecimig program.
View source ↗ - Newsglobenewswire.com·61d ago·Negative
Compass Therapeutics Provides Regulatory Update on Tovecimig in Biliary Tract Cancer Following FDA Feedback BOSTON, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the U.S. Food and Drug Administration (FDA) recommended that Compass conduct a trial demonstrating a survival benefit before proceeding wit
View source ↗ - Newsmarketbeat.com·61d ago·Negative
Compass Pathways Eyes 2027 COMP360 Launch as FDA Filing Nears Compass Pathways NASDAQ: CMPS said it expects to complete its rolling New Drug Application submission for its synthetic psilocybin treatment, COMP360, in the fourth quarter and continues to target a potential commercial launch for treatment-resistant depression in the first half of 2027.
View source ↗ - Newsbusinesswire.com·67d ago·Positive
Compass Pathways to Participate in TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit on September 23, 2026 LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that management will attend the TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit on September 23, 2026 and will participate in a fireside chat at 1:00
View source ↗ - News247wallst.com·69d ago·Neutral
Coinbase Jumps 6% on Compass Point Upgrade Ahead of Senate CLARITY Act Vote; Strategy Climbs 3%, MARA Slips Coinbase Global (NASDAQ:COIN | COIN Price Prediction) shares are up 6% to $185.
View source ↗ - Newsbusinesswire.com·72d ago·Positive
Strata Mental Health Solutions Awarded U.S. Healthcare Provider Training Grant from Compass Pathways to Develop Provider Training for COMP360 ATLANTA--(BUSINESS WIRE)--Strata Mental Health Solutions, the expert-led training and implementation partner preparing clinical networks to deliver psychedelic treatments, today announced it has been awarded one of the five U.S. HCP training grants awarded by Compass Pathways (Nasdaq: CMPS) to develop U.S. health care provider training programs for COMP360
View source ↗ - News247wallst.com·73d ago·Positive
Compass CEO Says 42% of Homes Took a Price Cut Compass (NYSE:COMP) CEO Robert Reffkin went on CNBC this morning with a striking data point and a buyer-friendly pitch.
View source ↗ - Newsprnewswire.com·73d ago·Positive
Fluence Selected by Compass Pathways to Develop Post-Approval COMP360 Provider Training New certificate program will prepare clinicians to support patients receiving COMP360 psilocybin treatment, if approved by the FDA NEW YORK, Sept. 10, 2026 /PRNewswire/ -- Fluence, a leading provider of professional education in psychedelic therapy, today announced that it has been selected by Compass Pathways plc (Nasdaq: CMPS) as a recipient of its U.S. healthcare provider training grant program.
View source ↗ - Newsbusinesswire.com·73d ago·Positive
Compass Pathways Announces U.S. Grant Program Recipients for the Development of Post-Approval COMP360 Provider Training LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today the U.S. grant program recipients to create training programs for healthcare providers (HCPs) that will be involved in the delivery of psychedelic treatments, such
View source ↗ - Newsbusinesswire.com·73d ago·Positive
Compass Pathways to Participate in Investor Conferences the Week of September 14th LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that management will participate in the following investor conferences the week of September 14th: H.C. Wainwright Annual Global Investment Conference – New York, NY: Fireside chat at 3:30pm ET on Sept
View source ↗ - Newsfxempire.com·74d ago·Positive
Compass Pathways Forecast: Breakout Could Target $22.51–$25.51 CMPS is testing a breakout after positive Phase 3 data, with a close above $15.40 potentially opening the way toward $22.51–$25.51.
View source ↗ - Newsproactiveinvestors.com·74d ago·Positive
Compass Pathways stock rises as 52-week data show lasting depression relief Compass Pathways (NASDAQ:CMPS) climbed 4% on Wednesday after new 52-week data from the company's Phase III study of COMP360, its investigational oral psilocybin treatment for treatment-resistant depression (TRD). The data, from the open-label Part C portion of Study '005, showed sustained efficacy with an infrequent dosing paradigm of two to four times per year.
View source ↗ - Newsbusinesswire.com·74d ago·Positive
Compass Pathways' New 52-Week Topline Open-Label Data from Phase 3 COMP005 Trial Demonstrates Additional Benefit from Another COMP360 Dose in Part C Extending Durability Out to 1 Year LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today the topline 52-week results (Part C) from its Phase 3 COMP005 trial of COMP360, a synthetic, proprie
View source ↗ - Newsbusinesswire.com·80d ago·Neutral
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to thirty-one newly hired non-executive employees. The equity awards were granted on September 1, 2026
View source ↗ - Newsbusinesswire.com·81d ago·Positive
Compass Pathways Recognized as a 2026 Fierce 50 Breakthrough Honoree LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways, a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, has been named a 2026 Fierce 50 Breakthrough honoree by Fierce Pharma, Fierce Biotech and Fierce Healthcare. The Fierce 50 recognizes 50 individuals and organizations driving advancements in medicine, fostering innovation and shaping the future of bi
View source ↗ - Newsbusinesswire.com·82d ago·Positive
Compass Pathways to Participate in 2026 Cantor Global Healthcare Conference on September 9, 2026 LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that management will attend the 2026 Cantor Global Healthcare Conference on September 9, 2026 and will participate in a fireside chat at 3:20pm ET and a panel entitled “PSYCH! Accessing T
View source ↗ - Newsmarketwatch.com·87d ago·Neutral
Here's how the private-listing war between Zillow and Compass could cost home buyers and sellers Real-estate giants Compass and Zillow are battling over control of home listings. Consumer advocates and industry experts warn that buyers and sellers could pay a price.
View source ↗ - Newsseekingalpha.com·89d ago·Positive
Compass Pathways: There Are Different Scenarios To Be Considered In Clinical, Regulatory, And Commercialization Compass Pathways plc is rated Strong Buy with a $25–$30 fair value, reflecting a significant upside to current levels. Compass Pathways' COMP360 offers a capacity advantage over Spravato, enabling four times more patients per monitored hour and supporting higher peak sales estimates. Regulatory momentum is strong, but timing risk exists due to DEA rescheduling, which could create inter
View source ↗ - Newsseekingalpha.com·89d ago·Positive
Compass Pathways: Still A Buy, But The Exit Just Got Complicated COMPASS Pathways remains a Buy, but Eli Lilly's acquisition of AtaiBeckley narrows CMPS's long-term strategic options. COMP360's first-mover advantage in treatment-resistant depression is real but fragile, with approval targeted for H1 2027 and launch timelines described as fluid. BPL-003's short-duration sessions may offer superior site economics versus CMPS's 6-hour COMP360 protocol, raising competitive risks.
View source ↗ - Newsmarketbeat.com·102d ago·Negative
Compass Pathways Targets 2027 COMP360 Launch as FDA Filing Advances Compass Pathways NASDAQ: CMPS said it remains on track to complete a new drug application for COMP360, its investigational psilocybin treatment for treatment-resistant depression, in the fourth quarter of this year, with a potential U.S. launch expected in the first half of 2027.
View source ↗ - Newsmarketbeat.com·103d ago·Neutral
Compass Diversified Q2 Earnings Call Highlights Compass Diversified NYSE: CODI reported second-quarter results marked by double-digit growth in subsidiary adjusted EBITDA, improved operating cash flow and lower debt following the sale of Sterno's food service business, while maintaining its full-year 2026 outlook.
View source ↗ - Newsmarketbeat.com·106d ago·Neutral
Compass Minerals International Q3 Earnings Call Highlights Compass Minerals International NYSE: CMP reported fiscal third-quarter adjusted EBITDA of $39.9 million, compared with $41 million a year earlier, as stronger pricing in its salt and plant nutrition businesses was offset by lower highway de-icing volumes and higher production and distribution costs in salt.
View source ↗
Earnings
Tue, Nov 24(tomorrow)
Consensus estimate $0.75 per share
Typical surprise +1.3% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, May 11$0.73 vs $0.71beat
- Tue, Nov 25$0.67 vs $0.67beat
- Wed, May 14$0.65 vs $0.63beat
- Thu, Feb 6$0.60 vs $0.60beat
- Wed, May 15$0.59 vs $0.59beat
- Mon, Nov 20$0.54 vs $0.54miss
Estimates and results for CMPGY via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Congress trades
- Ro Khannahouse · CA17 · disclosed Oct 9, 2026 (28d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Mar 6, 2024 (26d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Nov 8, 2023 (26d later)Sell$1,001 - $15,000
- Daniel Goldmanhouse · NY10 · disclosed Aug 13, 2023 (34d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Apr 7, 2023 (28d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Mar 8, 2023 (26d later)Buy$15,001 - $50,000
- Shelley Moore Capitosenate · WV · disclosed Oct 16, 2017 (41d later)Buy$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
